Torsten Zimmermann

Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls

Henryk Barthel, Julia Luthardt, Georg Becker et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2011 · 96 citations

Neurodegenerative Diseases, Alzheimer's Disease, Mechanism Phase 0 +9

In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer’s disease patients

Andrea Varrone, Patrik Mattsson, Anton Forsberg et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 82 citations

Positron Emission Tomography, Neuroimaging Biomarkers, Neurodegenerative Diseases +12

In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106

Akihiro Takano, Fredrik Piehl, Jan Hillert et al. · EJNMMI Research · 2013 · 73 citations · Full text

The Developing Regorafenib Eye drops for neovascular Age‐related Macular degeneration (DREAM) study: an open‐label phase II trial

Antonia M. Joussen, Sebastián Wolf, Peter K. Kaiser et al. · British Journal of Clinical Pharmacology · 2018 · 55 citations · Full text

Long‐Term Azithromycin Therapy in Cystic Fibrosis Patients: A Study on Drug Levels and Sputum Properties

Ulrich Baumann, Malcolm King, Ernst M. App et al. · Canadian Respiratory Journal · 2004 · 51 citations · Full text